EUCTR2007-001906-26-FR进行中（未招募）1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patients
HEXAL Biotech ForschungsGmbH0 个研究点目标入组 300 人开始时间: 2008年7月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Known chronic renal insufficiency of at least 4 weeks duration; CKD stage at least 3 or higher
- •Male and female patients, age: = 18 years
- •Patients who are naïve to ESA treatment or previously ESA treated after 3 months of ESA-free period (i.v. or s.c.)
- •Patients with symptomatic anemia, defined as Hb level below 11.0 g/dL and not lower than or equal to 7.50 g/dL on at least 2 visits during the screening period
- •Adequate iron status, serum ferritin = 100 µg/L or transferrin saturation = 20%
- •Ability to follow study instructions and likely to complete all required visits and compliant with subcutaneous administration
- •Written informed consent of the patient.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Anemia of non-renal causes
- •Therapy with immunosuppressants (other than corticosteroids for chronic treatment) within 3 months before screening and during the study for patients with renal allograft in place or other chronic conditions (e.g. lupus erythematosus, rheumatic arthritis)
- •Patients previously treated with chronic dialysis within the last 6 months (exception: one session of acute dialysis)
- •Patients with acute deterioration of renal function during the screening phase according to the investigator’s judgment
- •Patients receiving any RBC/whole blood transfusion during the screening period
- •Primary hematological disorder (e.g. myeloma, myelodysplastic syndrome, sickle cell anemia, hematological malignancy, hemolytic anemia)
- •Evidence of uncontrolled diabetes mellitus (HbA1c > 10 % at visit -2)
- •Evidence of severe hepatic dysfunction (e.g. ALT and/or AST above 2x upper limit of normal range; or gamma-GT above 3x upper limit of normal range)
- •Clinical evidence of current uncontrolled or symptomatic hyperparathyroidism, defined as parathyroid hormone > 500 ng/L at visit -2.
- •Uncontrolled hypertension, defined as a systolic blood pressure of = 160 mmHg and a diastolic blood pressure measurement = 100 mmHg (average of two values with at least one day between measurements)
- •Congestive heart failure and/or angina pectoris [New York Heart Association (NYHA) class III and IV]
- •History of stroke or myocardial infarction during the last 6 months prior to visit -2
- •Ongoing treatment with phenprocoumon or other cumarin derivates
- •Thrombocytopenia (platelet count <100.000/µL) or leucopenia (white blood cell count < 2.000/µL)
- •Gastrointestinal bleeding within the last 6 months prior to visit -2 or hemolysis
- •Evidence of acute or chronic infection by a C-reactive protein value of > 30 mg/L
- •Suspicion or known PRCA (pure red cell aplasia)
- •Previously diagnosed HIV or acute hepatitis infection
- •History of epilepsy or epileptic seizures or treatment for epilepsy within the past 6 months prior to screening
- •Planned major surgery (with expected high blood loss) during the next 3 months or major surgery within the previous 3 months (except laser photocoagulation, access surgery)
- •Clinical evidence of active malignant diseases within the last 5 years (except non-melanoma skin cancer)
- •Pregnancy, breastfeeding women or women not using a highly effective birth control method (e.g. implants, injectables, combined oral contraceptives, IUD, sexual abstinence, vasectomised partner)
- •Known history of severe drug related allergies (eg anaphylactic shock)
- •Known allergy to one of the ingredients of the test product or hypersensitivity to mammalian-derived products
- •Known or suspicion of any non-compliance with respect to subcutaneous treatment
- •Simultaneous participation in another clinical study or participation in a study in the month preceding visit-2 or previously randomized in this study
- •Participation in another ESA study in the 3 months preceding visit -2
- •Any other condition which at the investigator's discretion may put the patient at risk or which may confound the study results.
研究者
相似试验
进行中（未招募）
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-ATHEXAL AG300
进行中（未招募）
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-BGHEXAL Biotech ForschungsGmbH300
进行中（未招募）
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-001906-26-SKHEXAL Biotech ForschungsGmbH300
进行中（未招募）
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-001906-26-DEHEXAL AG300
未知
3 期
Multicenter, double-blind randomized, controlled study for the treatment of involutional osteoporosisJPRN-jRCT2080220084ONO PHARMACEUTICAL CO.,LTD.